ArticleEye (London, England)2011
Mycophenolate mofetil monotherapy in the management of paediatric uveitis.
Article in Eye (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05540743 (The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort
Who cites it
15 citing papers in PubMed, 56 citations in OpenAlex.
- Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis.American journal of ophthalmology · 2017Trial
- Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatric rheumatology online journal · 2016Trial
- Systemic immunosuppressive therapy in juvenile idiopathic arthritis-associated uveitis.International ophthalmology · 2026Article
- Trends in immunomodulatory therapy for the treatment of chronic uveitis in the United States.Journal of ophthalmic inflammation and infection · 2025Article
- Use of immunomodulators in non-infectious uveitis: lights and shadows.Eye (London, England) · 2024Review
- Update on the management of uveitis in children: an overview for the clinician.Expert review of ophthalmology · 2019Article
- Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis.Ocular immunology and inflammation · 2018Article
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- Morphological assessment of the retina in uveitis.Journal of ophthalmic inflammation and infection · 2016Article
- Juvenile idiopathic arthritis-associated uveitis.Pediatric rheumatology online journal · 2016Review
- Uveitis associated with juvenile idiopathic arthritis.Nature reviews. Rheumatology · 2015Review
- [Therapy of intermediate uveitis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2014Article
- Treatment of uveitis associated with juvenile idiopathic arthritis.Current rheumatology reports · 2014Review
- Paediatric use of mycophenolate mofetil.British journal of clinical pharmacology · 2013Review
- Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate effectiveness and safety of mycophenolate mofetil (MMF) monotherapy in paediatric autoimmune uveitis.
methodsWe reviewed medical records of patients, 18 years of age or younger, with autoimmune uveitis treated with MMF at our practice from 2005 to 2009. The dose and duration of MMF therapy, inflammation status, visual acuity, previous immunomodulatory therapies, and adverse effects were recorded. In addition, the following subgroups were defined: (1) Durable Disease Control: patients whose uveitis remained quiescent for at least 2 years on MMF monotherapy, with no more than two flare-ups successfully treated with an increase in MMF dosage and/or a short course (<1 month) of corticosteroids; (2) Short-term Inflammation Control: patients whose uveitis remained quiescent for less than 2 years, with no more than one flare-up successfully treated with an increase in MMF dosage and/or a short course of corticosteroids, or who initially achieved inflammation control but discontinued MMF because of significant adverse effects.
resultsA total of 38 out of 52 patients (73.1%) obtained inflammation control following 2 months of MMF monotherapy, achieving ≤ 0.5+ grading in anterior chamber cell/flare and vitreous haze. In the cross-sectional analysis, 25 patients (48.1%) met the criteria for Durable Disease Control, and 13 others (25.0%) qualified for Short-term Inflammation Control. Visual acuity remained stable or improved in 94.2% of the study population. Six patients (11.5%) discontinued MMF because of significant adverse effects, the most common of which was gastrointestinal disturbances.
conclusionMMF monotherapy appears to be an effective and safe treatment in paediatric autoimmune uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.